{"classes":[{"categories":[{"measurements":[{"comment":"The medians and 95% CIs for OS were calculated based on Kaplan-Meier estimates. Insufficient events to calculate a reliable upper 95% CI.","groupId":"OG000","lowerLimit":"2.6","upperLimit":"NA","value":"9.1"},{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"20.7","value":"10.4"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"9.8","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"OS will be summarized using Kaplan-Meier estimates. Will also assess OS in patients stratified by PD-L1 expression levels in the tumor microenvironment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG000","title":"Group 1 (CYT107, Atezolizumab)"},{"description":"Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV","id":"OG001","title":"Group 2 (Atezolizumab)"},{"description":"Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nAtezolizumab: Given IV\n\nGlycosylated Recombinant Human Interleukin-7: Given IM","id":"OG002","title":"Safety Run in Phase"}],"paramType":"MEDIAN","populationDescription":"The PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.","reportingStatus":"POSTED","timeFrame":"Time interval between start of treatment to death due to any cause, assessed up to 48 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}